ApoE lipidation state directs immunometabolic reprogramming of human microglia

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION ApoE ε4 is the strongest genetic risk factor for Alzheimer’s disease (AD). Emerging evidence suggests that ApoE4 increases AD risk by disrupting microglial metabolism and function. However, whether ApoE lipidation state contributes to...

The effects of improved access to diabetes medications on risk of Alzheimer’s disease and related dementias

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION Diabetes is associated with elevated risk of Alzheimer’s disease and related dementias (ADRD). Disease management with pharmaceutical therapies may mitigate this increased risk, but access and use of diabetes therapies are limited,...

Data‑driven cognitive composites predict Aβ‑related decline and progression to MCI: the ADOPIC study

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION Cognitive composites offer greater sensitivity to amyloid beta (Aβ)-related decline compared to individual tests for tracking longitudinal cognitive change. We developed and validated data-driven composites from the harmonized Alzheimer’s...

Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION Effective disease-modifying therapies remain unavailable for neurodegenerative diseases (NDDs). Tyrosine kinase inhibitors (TKIs) indicated for chronic myeloid leukemia (CML) have been hypothesized to modulate the pathological mechanisms...

Associations between plasma biomarker levels and quantitative postmortem neuropathologic measures in Alzheimer’s disease and related dementias

by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia

Abstract INTRODUCTION Validation of Alzheimer’s disease blood-based biomarkers (BBMs) has relied largely on amyloid beta (Aβ) and tau positron emission tomography (PET), with limited quantitative neuropathologic correlation studies. We examined associations...

MIND diet–related plasma proteins are associated with Alzheimer’s disease risk

by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia

Abstract INTRODUCTION Adherence to the Mediterranean–Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet is associated with reduced dementia risk, but underlying mechanisms remain unclear. METHODS Plasma proteomics (SomaScan...